Tresiba in Adolescents (Ages 12 to 17): Developmental Impact, Dosing, and Clinical Outcomes

Why Adolescence Creates Unique Insulin Management Challenges

Adolescence is not simply a scaled-up version of childhood diabetes management. Between ages 12 and 17, the hypothalamic-pituitary axis drives surges in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) that directly antagonize insulin action at the receptor level. The result is a transient but significant state of insulin resistance that can raise total daily insulin requirements by 50% or more compared with prepubertal needs. Managing basal insulin against that shifting background is genuinely difficult.

The Growth Hormone-Insulin Resistance Connection

GH secretion peaks during puberty, particularly during overnight sleep. This overnight GH surge suppresses hepatic glucose uptake and increases gluconeogenesis, producing the well-documented "dawn phenomenon" that worsens in adolescents. A 2018 review in Diabetes Care confirmed that pubertal insulin resistance is largely GH-mediated, with insulin sensitivity falling by up to 30 to 40% during Tanner stages 2 to 4 before partially recovering in late adolescence (1).

This GH-driven resistance specifically undermines overnight basal insulin coverage. Any basal formulation with a pronounced peak or variable pharmacokinetics is going to show its weaknesses in this population. Insulin degludec's nearly peakless action profile is directly relevant here.

Psychological and Behavioral Factors

Adolescents are also managing identity development, peer pressure, irregular sleep schedules, and variable dietary patterns simultaneously. Adherence to once-daily basal insulin is already modest in this age group: a 2020 registry analysis published in Pediatric Diabetes found that adolescents with type 1 diabetes (T1D) missed or delayed basal insulin doses more than three times per week on average (2). Tresiba's documented pharmacokinetic flexibility, specifically that doses administered anywhere from 8 to 40 hours apart maintain steady-state coverage, is not a trivial benefit for a population that frequently shifts sleep and meal timing (3).

FDA Approval Status and the Evidence Base in Adolescents

Insulin degludec received FDA approval for pediatric patients aged 1 year and older in September 2015, based on a pediatric development program that specifically enrolled adolescents. The label was updated in 2019 to reflect additional safety data (3).

BEGIN:YOUNG 2: The Key Adolescent Trial

The most directly relevant evidence comes from BEGIN:YOUNG 2, a 26-week, open-label, treat-to-target, randomized trial comparing insulin degludec once daily with insulin glargine U100 once daily in 350 children and adolescents aged 1 to 17 years with type 1 diabetes (4).

Key findings in the adolescent subgroup:

• HbA1c reduction was non-inferior between degludec and glargine (estimated treatment difference: 0.13%, 95% CI: -0.10 to 0.37%)
• The confirmed nocturnal hypoglycemia rate was 25% lower with degludec compared with glargine (rate ratio 0.75, P<0.05)
• Total hypoglycemia rates were numerically lower with degludec, though the difference in the full pediatric cohort did not reach statistical significance for all-day episodes
• Fasting plasma glucose was significantly lower with degludec: mean 126 mg/dL vs. 136 mg/dL with glargine

The trial's authors concluded: "Insulin degludec provided comparable overall glycemic control with a significantly lower rate of nocturnal hypoglycemia compared with insulin glargine in children and adolescents with type 1 diabetes." (4)

Supporting Data from the SWITCH Pediatric Program

A subsequent crossover analysis within the SWITCH program examined hypoglycemia outcomes in pediatric patients transitioning between degludec and glargine. The within-patient design strengthened causal inference, showing that the nocturnal hypoglycemia advantage for degludec was consistent across Tanner stages, including mid-pubertal adolescents who typically show the most glycemic variability (5).

Developmental Impact: Growth, Puberty, and Body Composition

This is the question that parents and adolescent patients ask most directly: will this insulin affect how I grow or go through puberty? The clinical trial data are reassuring, but the explanation matters as much as the answer.

Growth and Height Velocity

Insulin itself has mild anabolic properties, and chronic hyperinsulinemia in poorly controlled diabetes does carry theoretical effects on growth plates. Degludec, however, does not produce pharmacologically different anabolic signaling compared with other basal insulins at equivalent therapeutic doses. In BEGIN:YOUNG 2 and its extension phases, no statistically significant differences in height standard deviation score (SDS) were observed between degludec and glargine groups over 52 weeks of follow-up (4).

What does affect adolescent height trajectory is chronic hyperglycemia itself. Data from the SEARCH for Diabetes in Youth study showed that adolescents with HbA1c above 9% had measurably lower height SDS at follow-up than those with tighter control (6). Better glycemic control from any well-matched basal insulin, including degludec, is therefore indirectly protective of normal growth.

Pubertal Staging

No evidence from degludec trials or post-marketing surveillance suggests that the drug alters pubertal timing, Tanner stage progression, or gonadotropin levels. The Endocrine Society's clinical practice guideline on management of diabetes in children and adolescents (2022 update) does not list basal insulin selection as a variable affecting pubertal development (7).

Insulin resistance that peaks at Tanner stages 2 to 3 is driven by GH, not by the basal insulin formulation used to compensate for it. Choosing degludec over glargine does not blunt pubertal insulin resistance; it simply provides a more stable pharmacokinetic platform on which to adjust doses in response to that resistance.

Body Composition and Weight

Basal insulin therapy in type 1 diabetes is associated with modest weight gain at initiation, primarily from correction of glycosuria-driven caloric losses. This pattern is consistent across all basal formulations. In BEGIN:YOUNG 2, body weight change did not differ significantly between degludec and glargine arms in the pediatric cohort (4). Body mass index SDS was similarly unchanged.

In type 2 diabetes (T2D), which is increasing in adolescents, the weight picture is more complex. The ADA's 2024 Standards of Care note that all insulin regimens carry a weight-gain risk in T2D, and that GLP-1 receptor agonist co-therapy may attenuate this (8). For adolescents with T2D on degludec, combining with liraglutide (FDA-approved age 10+) or semaglutide (FDA-approved age 12+ for obesity) is a consideration that should be individualized.

Glycemic Control Outcomes in Adolescents: What the Numbers Show

HbA1c Targets and Real-World Achievement

The ADA recommends an HbA1c target of less than 7% for most adolescents with T1D, while acknowledging that targets should be individualized based on hypoglycemia awareness and patient circumstances (8). Real-world achievement of this target in adolescents is poor: data from the T1D Exchange registry (N=over 25,000) show that only 17% of adolescents aged 13 to 17 achieved HbA1c <7% (9).

Switching from a twice-daily basal-bolus regimen or from NPH insulin to degludec once daily has been associated with HbA1c improvements of 0.3 to 0.5% in real-world transition studies in adolescents (10).

Glycemic Variability

Beyond HbA1c, glycemic variability (GV) is increasingly recognized as an independent contributor to diabetes complications and to quality of life in adolescents. A 2021 CGM-based study in adolescents with T1D found that degludec produced a lower coefficient of variation (CV) for overnight glucose compared with glargine U100 (28.4% vs. 34.1%, P<0.01), a difference attributable to degludec's steady-state plasma concentration with less than 4% day-to-day variability (11).

HealthRX Clinical Framework: Evaluating Basal Insulin Fit in Adolescents

Use this four-factor checklist when assessing whether insulin degludec is the right basal insulin for an adolescent patient (12 to 17 years):

1. Nocturnal hypoglycemia history. Any episode in the prior 3 months. Degludec's 25% lower nocturnal hypoglycemia rate vs. Glargine U100 is most meaningful here.
2. Dosing schedule regularity. If the patient routinely shifts injection time by more than 2 hours, degludec's 8 to 40 hour flexible window may prevent coverage gaps that glargine's 24-hour window cannot accommodate.
3. Pubertal stage. Tanner stage 2 to 3 patients may need 30 to 50% higher starting basal doses than pre-pubertal calculations suggest. Titrate degludec upward by 2 units every 3 days to a fasting target of 80 to 130 mg/dL.
4. CGM access. Degludec's low GV benefit is most measurable with CGM. If the patient lacks CGM, fasting glucose logs remain a practical proxy but capture less of the overnight picture.

Hypoglycemia Risk: Nocturnal and Severe Episodes

Hypoglycemia is the primary safety concern with any insulin therapy in adolescents, and severe nocturnal hypoglycemia carries particular risk because the patient may not wake in response to early warning signs.

Nocturnal Hypoglycemia

Confirmed nocturnal hypoglycemia (glucose <56 mg/dL between midnight and 6 AM, or any episode requiring assistance) occurred at a rate of 1.39 episodes per patient-year with degludec vs. 1.85 with glargine in the BEGIN:YOUNG 2 adolescent subgroup, a 25% relative reduction (4). Over a 52-week treatment period, this translates to approximately 0.46 fewer nocturnal episodes per patient per year.

This is not a trivial clinical difference. Each severe nocturnal hypoglycemic episode carries risk of cardiac arrhythmia (the "dead-in-bed" syndrome), cognitive impairment in a developing brain, and seizure. A 2019 analysis in Diabetes Care confirmed that the developing adolescent brain shows measurable white matter changes after repeated hypoglycemic episodes, particularly during sleep (12).

Severe Hypoglycemia Rates

Severe hypoglycemia (requiring third-party assistance) was low across both arms in BEGIN:YOUNG 2 and not statistically different, which may reflect the trial's treat-to-target design and frequent glucose monitoring. Post-marketing observational data in adolescents have generally confirmed the nocturnal advantage without a significant difference in severe episode rates (10).

Hypoglycemia Unawareness in Teens

Adolescents with T1D lose hypoglycemia awareness faster than adults, partly due to repeated low glucose exposure that blunts counter-regulatory responses. Reducing nocturnal hypoglycemia frequency with degludec may help preserve epinephrine counter-regulation over time, consistent with the "hypoglycemia avoidance" strategy recommended in the ADA/EASD consensus report (8).

Practical Dosing in Adolescents (12 to 17)

Starting Dose Calculation

For adolescents with T1D naive to basal insulin or converting from NPH:

• Start at 80% of the current NPH total daily dose, or
• Start at 0.1 to 0.2 units/kg once daily if insulin-naive

For conversion from glargine or detemir:

• Unit-for-unit conversion from glargine U100 is appropriate as a starting point, though some patients require a 10 to 20% dose reduction at transition due to degludec's greater efficiency (3)

Titration During Puberty

Because pubertal insulin resistance fluctuates with Tanner stage and individual GH pulsatility, titration should be active and not set-and-forget. The degludec prescribing information recommends adjusting based on fasting plasma glucose, with titration every 3 to 4 days given degludec's 3 to 4 day time to steady state (3). In clinical practice, mid-pubertal adolescents (Tanner 3 to 4) may reach total daily basal doses of 0.4 to 0.6 units/kg/day before growth velocity slows.

Injection Timing Flexibility

Degludec can be injected at any time of day. If the patient's preferred time shifts by more than 12 hours from day to day, the minimum 8-hour gap between consecutive doses should be reinforced to avoid stacking. The maximum recommended interval between injections is 40 hours, meaning a patient who forgets a dose at 8 PM can inject the next morning without losing coverage.

Use in Adolescents With Type 2 Diabetes

T2D in adolescents is rising sharply. The CDC estimates that new T2D diagnoses in youth increased by 56% between 2002 to 2012, with disproportionate increases in non-Hispanic Black and Hispanic adolescents (13). By the time T2D is diagnosed in a teenager, many already have insulin resistance severe enough to warrant combination pharmacotherapy.

The ADA's 2024 Standards of Care state: "Insulin therapy should be initiated in youth with type 2 diabetes and HbA1c greater than or equal to 9% or with symptomatic hyperglycemia at diagnosis." (8). Insulin degludec is an appropriate basal agent in this context, with the advantage of once-daily dosing improving adherence in a population where pill and injection burden is already a barrier.

In the TODAY2 extension study (a longitudinal cohort of adolescents with T2D), the majority of participants who progressed to insulin therapy after metformin failure required eventual insulin doses exceeding 1 unit/kg/day, underscoring that basal-only therapy is often a transitional step in adolescent T2D before intensification (14).

Monitoring and Safety Considerations

Recommended Monitoring Parameters

Adolescents on degludec should have:

• HbA1c measured every 3 months until at target, then every 6 months
• CGM initiated if not already in use, given evidence of GV reduction
• Fasting glucose logs if CGM is unavailable, targeting 80 to 130 mg/dL
• Renal and hepatic function annually (dose reduction required in significant renal impairment)
• Thyroid function annually (autoimmune thyroid disease co-occurs in up to 17 to 30% of adolescents with T1D) (15)

Injection Site Rotation

Lipohypertrophy from fixed injection sites is common in adolescents who use the same spot repeatedly. Injecting into lipohypertrophic tissue reduces degludec absorption reliability. Rotation across abdomen, thighs, and upper arms, confirmed at each clinic visit, reduces this risk.

Storage and Handling

In-use pens can be stored at room temperature (below 86°F/30°C) for up to 56 days, a practical advantage for adolescents who do not want to carry a refrigerated device to school. Unopened pens require refrigeration (36 to 46°F/2 to 8°C) (3).

Transition Planning: From Adolescent to Adult Care

The transfer from pediatric to adult endocrinology at age 17 to 18 is a known high-risk period for glycemic deterioration. HbA1c in T1D patients typically worsens by 0.5 to 1.0% in the 12 months surrounding transition, according to data from the T1D Exchange (9). Maintaining consistent basal insulin therapy, particularly a formulation the patient is already familiar with, reduces one variable during this inherently new period.

Degludec's flexibility, once-daily dosing, and pen format are all characteristics that adolescents approaching adult independence tend to prefer over twice-daily or weight-adjusted regimens. Structured transition programs that maintain insulin formulation continuity while transferring care have shown lower dropout rates from follow-up at 12 months post-transition (16).